Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Jun;9(6):455-63.
doi: 10.1593/neo.07277.

Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer

Aleksandra Zapotoczna  1 , Giuseppe Sasso, John Simpson, Mack Roach 3rd
Affiliations
Review

Current role and future perspectives of magnetic resonance spectroscopy in radiation oncology for prostate cancer

Aleksandra Zapotoczna et al. Neoplasia. 2007 Jun.

Abstract

Prostatic neoplasms are not uniformly distributed within the prostate volume. With recent developments in three-dimensional intensity-modulated and image-guided radiation therapy, it is possible to treat different volumes within the prostate to different thresholds of doses. This approach has the potential to adapt the dose to the biologic aggressiveness of various clusters of tumor cells within the gland. The definition of tumor burden volume in prostate cancer can be facilitated by the use of magnetic resonance spectroscopy (MRS). The increasing sensitivity and specificity of MRS to the prostate is causing new interest in its potential role in the definition of target subvolumes at higher risk of failure following radical radiotherapy. Prostate MRS might also play a role as a noninvasive predictive factor for tumor response and treatment outcome. We review the use of MRS in radiation therapy for prostate cancer by evaluating its accuracy in the classification of aggressive cancer regions and target definition; its current role in the radiotherapy planning process, with special interest in technical issues behind the successful inclusion of MRS in clinical use; and available early experiences as a prognostic tool.

PubMed Disclaimer

References

    1. Seshadri M, Spernyak JA, Maiery PG, Cheney RT, Mazurchuk R, Bellnier DA. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome. Neoplasia. 2007;9(2):128–135. - PMC - PubMed
    1. Zechmann CM, Woenne EC, Brix G, Radzwill N, Ilg M, Bachert P, Peschke P, Kirsch S, Kauczor HU, Delorme S, et al. Impact of stroma on the growth, microcirculation, and metabolism of experimental prostate tumors. Neoplasia. 2007;9(1):57–67. - PMC - PubMed
    1. Zhao D, Jiang L, Hahn EW, Mason RP. Continuous lowdose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology. Neoplasia. 2005;7(7):678–687. - PMC - PubMed
    1. McPhail LD, McIntyre DJ, Ludwig C, Kestell P, Griffiths JR, Kelland LR, Robinson SP. Rat tumor response to the vasculardisrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis. Neoplasia. 2006;8(3):199–206. - PMC - PubMed
    1. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, Johnson TD, Rehemtulla A, Ross BD. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia. 2006;8(4):259–267. - PMC - PubMed

LinkOut - more resources